Compare CERT & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERT | MGTX |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 808.9M | 909.1M |
| IPO Year | 2020 | 2018 |
| Metric | CERT | MGTX |
|---|---|---|
| Price | $5.49 | $11.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $11.67 | ★ $24.57 |
| AVG Volume (30 Days) | ★ 4.1M | 778.4K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $418,838,000.00 | $81,391,000.00 |
| Revenue This Year | $4.18 | $141.38 |
| Revenue Next Year | $5.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 8.75 | ★ 144.57 |
| 52 Week Low | $4.45 | $6.31 |
| 52 Week High | $13.88 | $12.28 |
| Indicator | CERT | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 70.94 |
| Support Level | $5.08 | $7.10 |
| Resistance Level | $6.37 | $11.85 |
| Average True Range (ATR) | 0.36 | 0.61 |
| MACD | 0.02 | 0.26 |
| Stochastic Oscillator | 39.45 | 83.78 |
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.